FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3103758115> ?p ?o ?g. }

• W3103758115 endingPage "120082" @default.
• W3103758115 startingPage "120082" @default.
• W3103758115 abstract "• EGFR is a main target for anti-cancer therapy due to related signaling cascades. • Antibody-drug conjugates (ADCs) are composed of mAb, chemical linker and drug. • EGFR-targeted nanoparticles improve aqueous drug solubility and tumor targeting. • ADCs are clinically more developed than EGFR-targeted nanoparticles. The epidermal growth factor receptor (EGFR) belongs to the tyrosine kinase receptors family and is present in the epithelial cell membrane. Its endogenous activation occurs through the binding of different endogenous ligands, including the epidermal growth factor (EGF), leading to signaling cascades able to maintain normal cellular functions. Although involved in the development and maintenance of tissues in normal conditions, when EGFR is overexpressed, it stimulates the growth and progression of tumors, resulting in angiogenesis, invasion and metastasis, through some main cascades such as Ras/Raf/MAPK, PIK-3/AKT, PLC-PKC and STAT. Besides, considering the limitations of conventional chemotherapy that result in high toxicity and low tumor specificity, EGFR is currently considered an important target. As a result, several monoclonal antibodies are currently approved for use in cancer treatment, such as cetuximab (CTX), panitumumab, nimotuzumab, necitumumab and others are in clinical trials. Aiming to combine the chemotherapeutic agent toxicity and specific targeting to EGFR overexpressing tumor tissues, two main strategies will be discussed in this review: antibody-drug conjugates (ADCs) and antibody-nanoparticle conjugates (ANCs). Briefly, ADCs consist of antibodies covalently linked through a spacer to the cytotoxic drug. Upon administration, binding to EGFR and endocytosis, ADCs suffer chemical and enzymatic reactions leading to the release and accumulation of the drug. Instead, ANCs consist of nanotechnology-based formulations, such as lipid, polymeric and inorganic nanoparticles able to protect the drug against inactivation, allowing controlled release and also passive accumulation in tumor tissues by the enhanced permeability and retention effect (EPR). Furthermore, ANCs undergo active targeting through EGFR receptor-mediated endocytosis, leading to the formation of lysosomes and drug release into the cytosol. Herein, we will present and discuss some important aspects regarding EGFR structure, its role on internal signaling pathways and downregulation aspects. Then, considering that EGFR is a potential therapeutic target for cancer therapy, the monoclonal antibodies able to target this receptor will be presented and discussed. Finally, ADCs and ANCs state of the art will be reviewed and recent studies and clinical progresses will be highlighted. To the best of our knowledge, this is the first review paper to address specifically the EGFR target and its application on ADCs and ANCs." @default.
• W3103758115 created "2020-11-23" @default.
• W3103758115 creator A5007171717 @default.
• W3103758115 creator A5008585429 @default.
• W3103758115 creator A5034036072 @default.
• W3103758115 creator A5039999387 @default.
• W3103758115 creator A5043454458 @default.
• W3103758115 creator A5046789469 @default.
• W3103758115 creator A5059385020 @default.
• W3103758115 creator A5078351268 @default.
• W3103758115 creator A5079740601 @default.
• W3103758115 creator A5087731343 @default.
• W3103758115 date "2021-01-01" @default.
• W3103758115 modified "2023-10-11" @default.
• W3103758115 title "EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles" @default.
• W3103758115 cites W1496291653 @default.
• W3103758115 cites W1548539205 @default.
• W3103758115 cites W1560319602 @default.
• W3103758115 cites W1583454317 @default.
• W3103758115 cites W1653629692 @default.
• W3103758115 cites W1963675633 @default.
• W3103758115 cites W1965686857 @default.
• W3103758115 cites W1967593297 @default.
• W3103758115 cites W1968885065 @default.
• W3103758115 cites W1971983208 @default.
• W3103758115 cites W1972703248 @default.
• W3103758115 cites W1977161245 @default.
• W3103758115 cites W1983466982 @default.
• W3103758115 cites W1983921129 @default.
• W3103758115 cites W1984146494 @default.
• W3103758115 cites W1989315766 @default.
• W3103758115 cites W1992387856 @default.
• W3103758115 cites W1992817854 @default.
• W3103758115 cites W1998866448 @default.
• W3103758115 cites W1999023893 @default.
• W3103758115 cites W2002516695 @default.
• W3103758115 cites W2015495715 @default.
• W3103758115 cites W2019138771 @default.
• W3103758115 cites W2022222077 @default.
• W3103758115 cites W2023958195 @default.
• W3103758115 cites W2027342147 @default.
• W3103758115 cites W2034870197 @default.
• W3103758115 cites W2041343430 @default.
• W3103758115 cites W2045158653 @default.
• W3103758115 cites W2048881023 @default.
• W3103758115 cites W2056881172 @default.
• W3103758115 cites W2059485990 @default.
• W3103758115 cites W2059999746 @default.
• W3103758115 cites W2063044400 @default.
• W3103758115 cites W2064609604 @default.
• W3103758115 cites W2065157474 @default.
• W3103758115 cites W2066864375 @default.
• W3103758115 cites W2068734213 @default.
• W3103758115 cites W2068861972 @default.
• W3103758115 cites W2070030853 @default.
• W3103758115 cites W2073541926 @default.
• W3103758115 cites W2074885018 @default.
• W3103758115 cites W2078816993 @default.
• W3103758115 cites W2079700983 @default.
• W3103758115 cites W2088594432 @default.
• W3103758115 cites W2092888765 @default.
• W3103758115 cites W2093004080 @default.
• W3103758115 cites W2094449657 @default.
• W3103758115 cites W2095381863 @default.
• W3103758115 cites W2097480478 @default.
• W3103758115 cites W2099618978 @default.
• W3103758115 cites W2101123723 @default.
• W3103758115 cites W2101893838 @default.
• W3103758115 cites W2126378504 @default.
• W3103758115 cites W2129944198 @default.
• W3103758115 cites W2130584549 @default.
• W3103758115 cites W2131719301 @default.
• W3103758115 cites W2132537288 @default.
• W3103758115 cites W2134850272 @default.
• W3103758115 cites W2135897043 @default.
• W3103758115 cites W2150244588 @default.
• W3103758115 cites W2155329472 @default.
• W3103758115 cites W2161541244 @default.
• W3103758115 cites W2161744546 @default.
• W3103758115 cites W2170726961 @default.
• W3103758115 cites W2250377728 @default.
• W3103758115 cites W2277529550 @default.
• W3103758115 cites W2333980454 @default.
• W3103758115 cites W2394642790 @default.
• W3103758115 cites W2409704700 @default.
• W3103758115 cites W2410258802 @default.
• W3103758115 cites W2417431203 @default.
• W3103758115 cites W2417507171 @default.
• W3103758115 cites W2495836927 @default.
• W3103758115 cites W2578736186 @default.
• W3103758115 cites W2594175941 @default.
• W3103758115 cites W2596304756 @default.
• W3103758115 cites W2599074167 @default.
• W3103758115 cites W2603088210 @default.
• W3103758115 cites W2606965429 @default.
• W3103758115 cites W2614773512 @default.
• W3103758115 cites W2620474869 @default.
• W3103758115 cites W2724558203 @default.

• next